New treatment shows promise for refractory GERD patients

Anti-reflux mucosal ablation significantly benefits patients with reflux-predominant GERD unresponsive to PPI therapy.

• 71.4% of patients receiving mucosal ablation reported at least a 50% improvement in quality of life after 6 months, compared to just 3.6% in the sham group (p<0.001).
• Significant reductions in heartburn, regurgitation, and reflux episodes were observed, with 35.7% of patients able to discontinue PPIs.

This technique may change the surgical approach to managing refractory GERD.

• Improvements in endoscopic findings were noted, further supporting its efficacy.